Simplify Logo

Full-Time

Sr Manager

Corporate Regulatory Affairs

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Hardware
Biotechnology

Compensation Overview

$180k - $210kAnnually

Senior, Expert

San Carlos, CA, USA + 1 more

Category
Public Health
Biology & Biotech
Requirements
  • 5 + years of experience in Regulatory Affairs in the biotechnology or pharmaceutical industries
  • Strong analytical and problem-solving skills
  • Strong written and verbal communication skills, including the ability to interact effectively and to influence
  • Strong attention to detail
  • Customer focused and adaptable, with the ability to balance and manage multiple projects from multiple stakeholders to time and quality expectations
  • High functioning as both a team player and individual contributor
  • Bachelor’s or advanced degree preferred (M.S., Pharm.D., M.D., Ph.D.) in a scientific discipline
Responsibilities
  • Manages most aspects of company regulatory interface with domestic and international health authorities
  • Manages the development and deployment of the regulatory program that ensures aggressive product approval
  • Manages and may generate regulatory submission documents for new products or changes to existing health authorities' filings, including domestic and international submissions and registration
  • Manages the submissions of clinical study submissions
  • Determines governmental regulations affecting company processes and assures the processes are complete and accurate to ensure company compliance
  • Partners with various teams throughout organization (Clinical Operations, R&D, Quality, etc.) on projects
  • Works with clinical team to assure appropriate organization and data are used for regulatory submissions and clinical presentations
  • Provides guidance with localization and labeling requirements
  • Manages regulatory reporting

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Company Stage

IPO

Total Funding

$119.1M

Headquarters

Menlo Park, California

Founded

1998

Growth & Insights
Headcount

6 month growth

4%

1 year growth

10%

2 year growth

31%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments from firms like Intrinsic Edge Capital and Jackson Creek Investment Advisors indicate strong market confidence in Corcept's growth potential.
  • The appointment of experienced leaders like Roberto Vieira and Monica Tellado suggests a strategic focus on expanding into oncology and emerging markets.
  • Corcept's commitment to patient and medical education enhances its reputation and fosters better patient outcomes.

What critics are saying

  • Ongoing legal disputes, such as the antitrust lawsuit from Teva, could result in financial and operational setbacks.
  • The loss of the Korlym patent lawsuit to Teva poses a significant threat to Corcept's revenue stream from its flagship product.

What makes Corcept Therapeutics unique

  • Corcept Therapeutics specializes exclusively in cortisol modulation, setting it apart from broader-focused biopharmaceutical companies.
  • Their flagship product, Korlym, is the first FDA-approved treatment for hypercortisolism in Cushing's syndrome, giving them a unique market position.
  • Corcept's extensive R&D pipeline with over 1,000 discovered selective cortisol modulators highlights their commitment to innovation in this niche field.